Together this data further reinforces our hypothesis that the dominant behavior of S163R mutation is through decreased secretion of CTRP5 in RPE cells and suggests that gene augmentation provides a potential treatment option for L-ORD patients. The gene discussed is C1QTNF5; the disease is late-onset retinal degeneration.